Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Condition(s) studied

Investigational drug(s) / intervention(s)

ORKA-002: ORKA-002 administered by subcutaneous (SC) injection

Placebo: Placebo administered by subcutaneous (SC) injection

Study summary

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.

Eligibility

Primary outcome measure(s)

• Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16 — Week 16
  The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).
• Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse events (TEAEs) and TEAEs of of Special Interest (TEAESIs) — Day 1 through Week 48
  Incidence of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TEAEs), and treatment-emergent adverse events of special interest (TEASIs), and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms

Trial sites (39)

More Oruka Therapeutics, Inc. trials in Canada

Other trials for the same condition